The ARASAFE study showed that a 50 mg/m2 biweekly docetaxel regimen reduced severe side effects compared to the standard 75 mg/m2 triweekly regimen in mHSPC patients. The experimental regimen resulted ...
In total, 61 patients with 67 events in the EC-D arm and 76 patients with 79 events in the DC arm. Including patients with recurrence after breast cancer but unknown cause of death. Fig 1. Cumulative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results